All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Analysis on Effectiveness, Safety and Blood Lipid Levels of Atorvastatin Calcium with Ezetimibe in Coronary Heart Disease

Author(s): Jiangbo Yu, D. L. Zhu, Xiaoli Wang, Z. J. An and J. Y. Zhao
Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, 1Department of Endocrinology, Daqing Oilfield General Hospital, Daqing, Heilongjiang 163000, 2Department of Respiratory Medicine, Women’s and Children’s Hospital, Qingdao University, Qingdao, Shandong 266000, 3Intensive Care Unit, Harbin Red Cross Center hospital, Harbin, Heilongjiang 150001, China

Correspondence Address:
J. Y. Zhao, Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China, E-mail:

This study focuses to find out the influence of atorvastatin calcium with ezetimibe on the effectiveness, safety and blood lipid levels in coronary heart disease. 95 coronary heart disease individuals admitted between April 2020 and April 2023 were selected and were assigned as control (n=45) and research group (n=50). Control group received atorvastatin calcium monotherapy and the research group were given a combination of atorvastatin calcium and ezetimibe. The effectiveness and adverse effects like gastrointestinal reactions, myalgia, loss of appetite and rash were comparatively analyzed. Blood lipid levels (low and high-density lipoprotein cholesterol, total cholesterol and triglyceride) were evaluated. Further, serum inflammatory indices namely, tumor necrosis factor-alpha, interleukin-6 and C-reactive protein were analyzed. Similarly oxidative stress indices (myeloperoxidase, malonyldialdehyde and superoxide dismutase) were compared between both the groups. The research group was found to have an evidently higher total effective rate and a similar incidence of total adverse reactions with the control group. Marked reduction in low density lipoprotein cholesterol, total cholesterol, triglyceride, tumor necrosis factor-alpha, interleukin-6, C-reactive protein, myeloperoxidase and malonyldialdehyde in the research group after treatment was found; while an evident increase in high-density lipoprotein cholesterol and superoxide dismutase were identified, which was higher than the baseline and the control group. Conclusively, atorvastatin calcium plus ezetimibe is effective and safe in treating coronary heart disease, and can significantly ameliorate blood lipid levels, serum inflammatory and oxidative stress indices.

Full-Text | PDF

Google scholar citation report
Citations : 66710

Indian Journal of Pharmaceutical Sciences received 66710 citations as per google scholar report